The Aeromedical Isolation Team (AIT, or SMART-AIT) of the US Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick, Maryland was a military rapid response team with worldwide airlift capability designed to safely evacuate and manage contagious patients under high-level (BSL-4) bio-containment conditions. [1] Created in 1978, [2] during its final years the AIT was one of MEDCOM’s Special Medical Augmentation Response Teams (SMART teams) comprising a portable containment laboratory along with its transit isolators for patient transport. Contingency missions included bioterrorism scenarios as well as the extraction of scientists with exotic infections from remote sites in foreign countries. The AIT trained continuously and was often put on alert status, but only deployed for “real world” missions four times. The AIT was decommissioned in 2010 and its mission was assumed by one of the US Air Force’s Critical Care Air Transport Teams (CCATTs).
The AIT was created in 1978 for purposes of contingency air evacuation of a hypothetical USAMRIID researcher who might become exposed to a highly infectious pathogen while undertaking endemic surveillance in remote areas of the world where a suspected or known disease outbreak was occurring. At the core of AIT operations was its specialized equipment, notably the Aircraft Transit Isolator (ATI). Developed by Vickers in the U.K. in the 1970s [4] — and manufactured in later years by Elwyn Roberts Isolators, Shropshire, UK, until 2007 — the ATI was a self-contained unit capable of transporting a patient with a highly virulent disease and at the same time providing maximum microbiological security while full nursing care and treatment are rendered. It was designed to minimize the risk of transmission to air crews and caregivers, whether military or civilian. The interior of the isolator was maintained at a pressure negative to the external environment by a high-efficiency particulate air (HEPA) filtered blower. The isolator could be attached directly to a transfer port, situated on the external wall of the main USAMRIID building, to allow movement of the patient into a BSL-4 medical care suite without exposing the environment to the patient. While moving the isolator, team members wore protective suits and positive-pressure, HEPA-filtered Racal hoods (manufactured by Racal Health & Safety, Inc, Frederick, Maryland). [3]
Throughout its existence the AIT was associated with a BSL-4 Medical Containment Suite (MCS, called “the Slammer”) at USAMRIID for ICU-level patient care under biocontainment. The MCS was built in 1969 and became operational in 1972; it was the destination to which contagious patients were to be removed by the AIT. Over the years the scope of the AIT/MCS mission was expanded to include U.S. military personnel, the U.S. Centers for Disease Control and Prevention, and U.S. citizens or foreign nationals deemed to be in need of service by the U.S. Department of State. Occasionally, the AIT trained with similar teams of foreign allies. [5]
This section needs expansion. You can help by adding to it. (May 2012) |
In 2007, due to the death of Mr Roberts, the ATI and associated products ceased to be manufactured. During 2008–2010, the AIT began preliminary training with, and testing of, a new transit isolator product — the Patient Isolation Unit (PIU) — developed by the Gentex Corporation under a contract with the U.S. Air Force.
The AIT was decommissioned — along with the MCS — in 2010 and its mission was assumed by one of the US Air Force’s Critical Care Air Transport Teams (CCATTs). The Air Force's capabilities, however, do not meet the standard of biocontainment (BSL-4) facilities, [6] but rather represent enhanced patient isolation. No BSL-4 ICU facility has replaced the Army's former MCS to date.
A biosafety level (BSL), or pathogen/protection level, is a set of biocontainment precautions required to isolate dangerous biological agents in an enclosed laboratory facility. The levels of containment range from the lowest biosafety level 1 (BSL-1) to the highest at level 4 (BSL-4). In the United States, the Centers for Disease Control and Prevention (CDC) have specified these levels in a publication referred to as BMBL. In the European Union, the same biosafety levels are defined in a directive. In Canada the four levels are known as Containment Levels. Facilities with these designations are also sometimes given as P1 through P4, as in the term P3 laboratory.
Fort Detrick is a United States Army Futures Command installation located in Frederick, Maryland. Fort Detrick was the center of the U.S. biological weapons program from 1943 to 1969. Since the discontinuation of that program, it has hosted most elements of the United States biological defense program.
Viral hemorrhagic fevers (VHFs) are a diverse group of animal and human illnesses. VHFs may be caused by five distinct families of RNA viruses: the families Filoviridae, Flaviviridae, Rhabdoviridae, and several member families of the Bunyavirales order such as Arenaviridae, and Hantaviridae. All types of VHF are characterized by fever and bleeding disorders and all can progress to high fever, shock and death in many cases. Some of the VHF agents cause relatively mild illnesses, such as the Scandinavian nephropathia epidemica, while others, such as Ebola virus, can cause severe, life-threatening disease.
The Hot Zone: A Terrifying True Story is a best-selling 1994 nonfiction thriller by Richard Preston about the origins and incidents involving viral hemorrhagic fevers, particularly ebolaviruses and marburgviruses. The basis of the book was Preston's 1992 New Yorker article "Crisis in the Hot Zone".
The United States Army Medical Research Institute of Infectious Diseases is the U.S Army's main institution and facility for defensive research into countermeasures against biological warfare. It is located on Fort Detrick, Maryland, near Washington, D.C., and is a subordinate lab of the United States Army Medical Research and Development Command (USAMRDC), headquartered on the same installation.
One use of the concept of biocontainment is related to laboratory biosafety and pertains to microbiology laboratories in which the physical containment of pathogenic organisms or agents is required, usually by isolation in environmentally and biologically secure cabinets or rooms, to prevent accidental infection of workers or release into the surrounding community during scientific research.
The Critical Care Air Transport Team (CCATT) concept dates from 1988, when Col. P.K. Carlton and Maj. J. Chris Farmer originated the development of this program while stationed at U.S. Air Force Hospital Scott, Scott Air Force Base, Illinois. Dr. Carlton was the Hospital Commander, and Dr. Farmer was a staff intensivist. The program was developed because of an inability to transport and care for a patient who became critically ill during a trans-Atlantic air evac mission in a C-141. They envisioned a highly portable intensive care unit (ICU) with sophisticated capabilities, carried in backpacks, that would match on-the-ground ICU functionality.
In health care facilities, isolation represents one of several measures that can be taken to implement in infection control: the prevention of communicable diseases from being transmitted from a patient to other patients, health care workers, and visitors, or from outsiders to a particular patient. Various forms of isolation exist, in some of which contact procedures are modified, and others in which the patient is kept away from all other people. In a system devised, and periodically revised, by the U.S. Centers for Disease Control and Prevention (CDC), various levels of patient isolation comprise application of one or more formally described "precaution".
Positive pressure personnel suits (PPPS)—or positive pressure protective suits, informally known as "space suits", "moon suits", "blue suits", etc.—are highly specialized, totally encapsulating, industrial protection inflatable garments worn only within special biocontainment or maximum containment (BSL-4) laboratory facilities. These facilities research dangerous pathogens which are highly infectious and may have no treatments or vaccines available. These facilities also feature other special equipment and procedures such as airlock entry, quick-drench disinfectant showers, special waste disposal systems, and shower exits.
The United States Biological Defense Program—in recent years also called the National Biodefense Strategy—refers to the collective effort by all levels of government, along with private enterprise and other stakeholders, in the United States to carry out biodefense activities.
Ebola, also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a viral hemorrhagic fever in humans and other primates, caused by ebolaviruses. Symptoms typically start anywhere between two days and three weeks after infection. The first symptoms are usually fever, sore throat, muscle pain, and headaches. These are usually followed by vomiting, diarrhoea, rash and decreased liver and kidney function, at which point some people begin to bleed both internally and externally. It kills between 25% and 90% of those infected – about 50% on average. Death is often due to shock from fluid loss, and typically occurs between six and 16 days after the first symptoms appear. Early treatment of symptoms increases the survival rate considerably compared to late start. An Ebola vaccine was approved by the US FDA in December 2019.
In 2014, an outbreak of Ebola virus disease in the Democratic Republic of the Congo (DRC) occurred. Genome sequencing has shown that this outbreak was not related to the 2014–15 West Africa Ebola virus epidemic, but was of the same EBOV species. It began in August 2014 and was declared over in November of that year, after 42 days without any new cases. This is the 7th outbreak there, three of which occurred during the period of Zaire.
Four laboratory-confirmed cases of Ebola virus disease occurred in the United States in 2014. Eleven cases were reported, including these four cases and seven cases medically evacuated from other countries. The first was reported in September 2014. Nine of the people contracted the disease outside the US and traveled into the country, either as regular airline passengers or as medical evacuees; of those nine, two died. Two people contracted Ebola in the United States. Both were nurses who treated an Ebola patient; both recovered.
Organizations from around the world responded to the West African Ebola virus epidemic. In July 2014, the World Health Organization (WHO) convened an emergency meeting with health ministers from eleven countries and announced collaboration on a strategy to co-ordinate technical support to combat the epidemic. In August, they declared the outbreak an international public health emergency and published a roadmap to guide and coordinate the international response to the outbreak, aiming to stop ongoing Ebola transmission worldwide within 6–9 months. In September, the United Nations Security Council declared the Ebola virus outbreak in the West Africa subregion a "threat to international peace and security" and unanimously adopted a resolution urging UN member states to provide more resources to fight the outbreak; the WHO stated that the cost for combating the epidemic will be a minimum of $1 billion.
The Aeromedical Biological Containment System (ABCS) is an aeromedical evacuation capability devised by the U.S. Centers for Disease Control and Prevention (CDC) in collaboration with the U.S. Department of Defense (DoD) and government contractor Phoenix Air between 2007 and 2010. Its purpose is to safely air-transport a highly contagious patient; it comprises a transit isolator and an appropriately configured supporting aircraft. Originally developed to support CDC staff who might become infected while investigating avian flu and SARS in East Asia, it was never used until the 2014 Ebola virus epidemic in West Africa, transporting 36 Ebola patients out of West Africa.
Cases of the Ebola virus disease in Nigeria were reported in 2014 as a small part of the epidemic of Ebola virus disease which originated in Guinea that represented the first outbreak of the disease in a West African country. Previous outbreaks had been confined to countries in Central Africa.
A Racal suit is a protective suit with a powered air-purifying respirator (PAPR). It consists of a plastic suit and a battery-operated blower with HEPA filters that supplies filtered air to a positive-pressure hood. Racal suits were among the protective suits used by the Aeromedical Isolation Team (AIT) of the United States Army Medical Research Institute of Infectious Diseases to evacuate patients with highly infectious diseases for treatment.
An isolation pod is a capsule which is used to provide medical isolation for a patient. Examples include the Norwegian EpiShuttle and the USAF's Transport Isolation System (TIS) or Portable Bio-Containment Module (PBCM), which are used to provide isolation when transporting patients by air.
In August–November 1976, an outbreak of Ebola virus disease occurred in Zaire. The first recorded case was from Yambuku, a small village in Mongala District, 1,098 kilometres (682 mi) northeast of the capital city of Kinshasa.
John J. Lowe is an American infectious disease scientist, assistant vice chancellor for health security at University of Nebraska Medical Center, and associate professor in the Department of Environmental, Agricultural and Occupational Health at University of Nebraska Medical Center College of Public Health. In 2014, he led Nebraska Medicine hospital’s effort to treat and care for Ebola virus disease patients and led the University of Nebraska Medical Center’s coronavirus disease 2019 response efforts.
{{cite book}}
: CS1 maint: multiple names: authors list (link)